Drug development

#Drug development #Drug discovery #Drug targets

Genetic modifiers: Why drug developers should care

Sebastian Nijman, Chief Scientific Officer, Scenic Biotech, explains why harnessing genetic modifiers holds great potential to address the present drug target vacuum and why every drug developer should care about them. According to the National Institute of Health (NIH), approximately 500 of the many thousands of human diseases have an approved… Read More

#Exclusive Content #News

#Clinical trials #Covid-19 #Drug development

ICON supports Pfizer and BioNTech on the investigational COVID-19 vaccine trial

ICON, provider of outsourced drug and device development and commercialisation services to the pharmaceutical, biotechnology and medical device industries and government and public health organisations, has announced it provided clinical trial services to the Pfizer and BioNTech investigational COVID-19 vaccine programme. Pfizer and BioNTech announced positive efficacy results from a… Read More

#Covid-19 #News

#AI / data analytics / healthtech / informatics #Drug development #Drug discovery #Therapeutics

Boehringer Ingelheim and Google in R&D partnership

Boehringer Ingelheim has entered a collaborative agreement with Google Quantum AI (Google), focusing on researching and implementing cutting-edge use cases for quantum computing in pharmaceutical research and development (R&D), specifically including molecular dynamics simulations. The new partnership combines Boehringer Ingelheim’s leading expertise in the field of computer-aided drug design and… Read More

#Editor's Choice #News

#Drug development #Drug discovery #Life sciences #Narrated podcasts

2030 Life Sciences and Health in the Digital Age (Part 2)

The Pistoia Alliance has developed a research paper which sets out to consider what the life science, biopharma R&D and healthcare ecosystem might look like in 2030, in particular how the increasing adoption and sophistication of technology will affect companies and patients alike. This article is the second part of… Read More

#Podcasts

#Drug development

Funding boost for tech that translates novel plant molecules into medicines

Enveda Biosciences’ $4.9 million seed round of funding will enable the company to grow its medicinal plant dataset, enhance its technologies and algorithms to accelerate natural product drug discovery and advance its lead asset for liver fibrosis through preclinical development. The funding was led by True Ventures, with participation from… Read More

#News

#Drug development #Drug discovery #Therapeutics

Small molecule therapeutics: solubility with permeability to achieve better bioavailability

Technologies have been honed to overcome many of the challenges of administering BCS class II and IV small molecule therapeutics says John S. Vrettos, Senior Principal Scientist & Head of Formulation Development, Enteris BioPharma Small molecule drugs have traditionally dominated the treatment of human disease given their diverse mechanisms of… Read More

#Exclusive Content

#Biologics #Drug development #Drug discovery #Oncology #Therapeutics

International consortium awarded grant for first-in-class metastatic cancer treatment

ONA Therapeutics, Absolute Antibody and RIC – three leading European companies in the biotech landscape – have been awarded a Eurostars grant for a two-year project that will develop a proprietary biological drug with a unique mode of action for the treatment of various types of metastatic cancers. Taking the… Read More

#Cancer Research #News

#Drug development #Drug discovery #Target validation

Evotec milestones in Bristol Myers Squibb collaboration

Evotec has achieved key milestones in its partnership with Bristol Myers Squibb in the field of targeted protein degradation with the first two targets transitioning into drug discovery after completing a comprehensive target validation process. Evotec and Bristol Myers Squibb (the successor in interest to Celgene) initiated their long-term strategic… Read More

#News

#Biotechnology #Drug development #Drug discovery #Health #Life sciences #Narrated podcasts #Pharmaceutical

2030 Life Sciences and Health in the Digital Age (Part 1)

This article is the first in a two-part series based on The Pistoia Alliance report. Written in retrospect from the world as it is in 2030, it looks at how healthcare has changed in the intervening decade, covering the socio-economic and political evolutions that have happened, the subsequent effects on… Read More

#Podcasts

#Drug development

Galapagos and Gilead Sciences in new agreement

Gilead Sciences and Galapagos have agreed to amend their existing arrangement for the commercialisation and development of Jyseleca (filgotinib). This announcement follows a meeting with the US FDA related to the New Drug Application (NDA) for filgotinib in the treatment of rheumatoid arthritis (RA.) Based on the feedback received from the… Read More

#News

#AI / data analytics / healthtech / informatics #Antibodies #Biotechnology #Cancer research #Drug development #Oncology

AI-driven precision medicine for development of HMBD-001 in HER3-driven cancers

Hummingbird Bioscience, a clinical-stage biotech company focused on developing revolutionary therapies for hard-to-drug targets, is collaborating with Tempus, an expert in artificial intelligence and precision medicine. This will drive the development of Hummingbird’s lead clinical program, HMBD-001, as it advances into clinical trials in HER3-driven cancers, including those that harbour… Read More

#Cancer Research #News

#Drug development #Immune system

Schizophrenia may be similar to immune disorders, say scientists

A study by clinical scientists at The University of Manchester has shown that schizophrenia may – in some part – be caused by disordered functioning of the immune system. The first ever trial in schizophrenia of the powerful immune suppressant drug, Methotrexate, produced what the team described as ‘promising’ effects… Read More

#Editor's Choice #News

#Biologics / Biotechnology #Biomanufacturing #Cell therapy #Drug development

Cedars-Sinai biomanufacturing centre spurs cell therapies to help develop new drugs

Cedars-Sinai has launched a centre to manufacture the next generation of stem cell and gene therapies that will enable biomedical researchers, government medical programs, commercial entities and others to develop new biologic drugs and propel novel disease discoveries. Biologic drugs are produced from living organisms or contain components of living… Read More

#Editor's Choice #News

#AI / data analytics / healthtech / informatics #Biologics #Drug development

IDBS Polar launch streamlines biopharmaceutical development

IDBS has launched Polar biopharma lifecycle management (BPLM),  which is aimed at streamlining drug development and manufacturing in biopharma research. The development of biologics is a dynamic process and those who are most successful must be able to adapt to changes in process or technology rapidly. IDBS data has found… Read More

#News

#AI / data analytics / healthtech / informatics #Cell culture #Drug development

Ground-breaking techniques using AI predict cell growth

Ground-breaking research at Teesside University using artificial intelligence to predict the growth rate of living organisms could have far-reaching consequences in the field of pharmaceuticals and medical diagnostics. A team of researchers led by Dr Claudio Angione from the University’s School of Computing, Engineering and Digital Technology looked at how… Read More

#News